Crystal Pharmatech

Crystal Pharmatech is a specialized CDMO/CRO focused on overcoming critical solid-state and formulation challenges in small molecule drug development. Founded in 2010 and headquartered in Newark, USA, with significant operations in China, the company provides an integrated suite of services from API form selection and crystallization process development to formulation and GMP manufacturing. It has expanded its capabilities into the biologics space through its Crystal Bio Solutions division, offering nucleic acid synthesis and LNP formulation services. The company is privately held, has raised growth capital, and partners with biotechs globally to de-risk and accelerate drug programs.

Integrated 'Mol2Med™' platform encompassing solid-state research (polymorph/salt screening, absolute structure determination, crystallization development) and formulation development (Amorphous Solid Dispersions, mini-tablets, bioavailability enhancement) for small molecules, plus nucleic acid synthesis and LNP formulation via Crystal Bio Solutions.

Crystal Pharmatech competes in a crowded CDMO/CRO market against large, diversified players like Lonza, Catalent, and Thermo Fisher, as well as specialized solid-state chemistry firms. Its differentiation lies in its deep focus on crystallography and formulation science for insoluble drugs, combined with a cost-competitive operational base in China and a growing foothold in nucleic acid services.